Stocks and Investing
Stocks and Investing
Thu, August 11, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, August 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Maintained (ZNTL) at Strong Buy with Decreased Target to $55 on, Aug 10th, 2022
Andrew Fein of HC Wainwright & Co., Maintained "Zentalis Pharmaceuticals, Inc." (ZNTL) at Strong Buy with Decreased Target from $120 to $55 on, Aug 10th, 2022.
Andrew has made no other calls on ZNTL in the last 4 months.
There are 3 other peers that have a rating on ZNTL. Out of the 3 peers that are also analyzing ZNTL, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Andrew
- Bradley Canino of "Stifel" Maintained at Strong Buy with Decreased Target to $70 on, Friday, July 29th, 2022
- Tyler Van Buren of "Cowen & Co." Initiated at Buy on, Tuesday, July 12th, 2022
- Matthew Biegler of "Oppenheimer" Maintained at Buy with Decreased Target to $85 on, Tuesday, April 12th, 2022
Contributing Sources